Thus, we hypothesize here that IETD-fmk treatment could a) counteract the initial pro-inflammatory state of SIRS, by decreasing the release of IL-1β and depleting the excess of monocytes; and b) prevent the immunosuppressive state by inhibiting the production of IL-10 in the remaining live monocytes. The gene discussed is IL1B; the disease is systemic inflammatory response syndrome.